Skip to main content
Premium Trial:

Request an Annual Quote

Andre Pernet, Michael Knapp, James Knighton, Anne Kopf-Sill, Andrea Chow, Yvonne Linney, Seth Cohen, Peter Wagner

Premium

Andre Pernet has become the president of Quark Biotech. Pernet previously served as corporate officer and vice president, pharmaceutical products R&D at Abbott Laboratories. He was also chairman and CEO of the European genomic company Genset from 2000 to 2002. He is currently chairman of CURx Pharma and he also serves on the board of directors of Kaleidos Pharmaceuticals.


Caliper Technologies has reconfigured is executive management team. Michael Knapp, current chief technical officer and founder of the company; and James Knighton, chief financial officer, will leave the company. Knapp will stay with the company through December. Knighton will remain at the company into the first quarter of 2004. Caliper said it is “actively recruiting” a Massachusetts-based CFO.

Anne Kopf-Sill has become vice president, molecular diagnostics at Caliper. She was previously vice president, microfluidics R&D. Andrea Chow has become vice president, microfluidics R&D. In addition, two new executives have been recruited to the company. Yvonne Linney has become senior director, microfluidics marketing and product management. She was previously di-rector of marketing for genomics at Amersham. Seth Cohen has become director of application scientists. Before this, he was previously the program director of lead discovery at Millennium Pharmaceuticals.


Peter Wagner, chief technology officer, senior vice president, and founder of

Zyomyx

, has been named a Technology Pioneer by the World Economic Forum for his research in protein biochips.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.